Monthly Regulatory Roundup — June 2026

The FDA cleared twelve devices this period across laser, radiofrequency, LED light therapy, and intense pulsed light platforms. Clearances include Hemolase Fiber (Micro-Energy Medical Technology), CoolSeal Generator® (Hologic), PICOSURE WORKSTATION (Cynosure), LumiGlam Laser System (Beijing Sano), MILAN System (Lumenis), LASEmaR 1500 (Eufoton), VIVA combo RF System (Starmed), and multiple LED light therapy masks from Newdermo, Kaiyan, and CurrentBody. All received Substantially Equivalent determinations, meaning they meet predicate device standards.

Action items:

• Verify any newly purchased devices carry valid 510(k) clearance documentation
• Update your equipment inventory and compliance files
• Confirm marketing claims align with cleared indications only
• Train staff on any new device protocols before clinical use

Payless Compounders, LLC issued a Class II recall for compounded Semaglutide-Glycine-Cyanocobalamin Injectable (2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials) due to lack of assurance of sterility. This is an ongoing recall affecting multiple lot numbers. Any practice using compounded semaglutide or similar injectables from this supplier must act immediately.

Action items:

• Check inventory for Payless Compounders products; quarantine and remove immediately
• Notify patients who received injections from affected lots
• Verify your compounding pharmacy meets USP <797> standards and holds current state pharmacy board licensure
• Request certificates of analysis (CoA) and sterility testing documentation from all compounding suppliers
• Document all recall communications and corrective actions

The FDA's General and Plastic Surgery Devices Panel has formally opened a public docket and request for comments on dermal fillers. Multiple Federal Register notices establish the panel meeting and invite stakeholder input. This signals the agency is re-examining filler safety, efficacy, labeling, and classification—potentially the most significant regulatory action on fillers in years.

Action items:

• Monitor FDA.gov and the Federal Register for panel meeting dates and comment deadlines
• Review your filler inventory: product names, manufacturers, clearance status, and current labeling
• Audit your informed consent forms and patient education materials
• Prepare documentation of your filler training, adverse event tracking, and complication management protocols
• Consider submitting comments if your practice has relevant safety or efficacy data

Use this checklist to ensure your practice stays compliant across all June regulatory developments:

• Device documentation: Maintain copies of 510(k) clearance letters and predicate device information for all equipment
• Recall response: Subscribe to FDA recall alerts; establish a protocol for immediate inventory checks and patient notification
• Compounding oversight: Verify supplier credentials quarterly; request recent state pharmacy board inspection reports
• Labeling accuracy: Confirm all device marketing, patient materials, and social media claims match FDA-cleared indications
• Staff training: Document training on new devices and recall procedures; maintain records for at least 3 years
• Adverse events: Report serious device-related injuries to the FDA via MedWatch within 30 days

The dermal filler panel review is not routine. It reflects growing FDA scrutiny of filler safety, particularly around vascular occlusion, migration, and long-term biocompatibility. Expect potential changes to labeling requirements, training mandates, or classification levels. Practices should prepare for stricter documentation, possible new adverse event reporting thresholds, and potentially tighter restrictions on off-label use.

Prepare now:

• Document all filler-related complications, even minor ones
• Strengthen your injection technique training and credentialing
• Review your liability insurance coverage for filler-related claims
• Engage with professional organizations monitoring the panel process